These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 22496388)

  • 41. Prostaglandin E2 induces CYP1B1 expression via ligand-independent activation of the ERalpha pathway in human breast cancer cells.
    Han EH; Kim HG; Hwang YP; Song GY; Jeong HG
    Toxicol Sci; 2010 Apr; 114(2):204-16. PubMed ID: 20093341
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.
    Tolhurst RS; Thomas RS; Kyle FJ; Patel H; Periyasamy M; Photiou A; Thiruchelvam PT; Lai CF; Al-Sabbagh M; Fisher RA; Barry S; Crnogorac-Jurcevic T; Martin LA; Dowsett M; Charles Coombes R; Kamalati T; Ali S; Buluwela L
    Breast Cancer Res Treat; 2011 Jul; 128(2):357-68. PubMed ID: 20730598
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
    Filardo EJ; Quinn JA; Frackelton AR; Bland KI
    Mol Endocrinol; 2002 Jan; 16(1):70-84. PubMed ID: 11773440
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential role of psoriasin (S100A7) in estrogen receptor α positive and negative breast cancer cells occur through actin remodeling.
    Sneh A; Deol YS; Ganju A; Shilo K; Rosol TJ; Nasser MW; Ganju RK
    Breast Cancer Res Treat; 2013 Apr; 138(3):727-39. PubMed ID: 23535840
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antitumor activity of taspine by modulating the EGFR signaling pathway of Erk1/2 and Akt in vitro and in vivo.
    Zhang Y; Zheng L; Zhang J; Dai B; Wang N; Chen Y; He L
    Planta Med; 2011 Nov; 77(16):1774-81. PubMed ID: 21614750
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
    J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.
    Zhang Y; Su H; Rahimi M; Tochihara R; Tang C
    Int J Cancer; 2009 Nov; 125(9):2021-8. PubMed ID: 19588487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.
    Reinbothe S; Larsson AM; Vaapil M; Wigerup C; Sun J; Jögi A; Neumann D; Rönnstrand L; Påhlman S
    Biochem Biophys Res Commun; 2014 Feb; 445(1):163-9. PubMed ID: 24502950
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rapid characterization of a novel taspine derivative-HMQ1611 binding to EGFR by a cell membrane chromatography method.
    Du H; Lv N; Wang S; He L
    Comb Chem High Throughput Screen; 2013 May; 16(4):324-9. PubMed ID: 23270402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
    Fukui F; Hayashi SI; Yamaguchi Y
    J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
    Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fangchinoline inhibits cell proliferation via Akt/GSK-3beta/ cyclin D1 signaling and induces apoptosis in MDA-MB-231 breast cancer cells.
    Wang CD; Yuan CF; Bu YQ; Wu XM; Wan JY; Zhang L; Hu N; Liu XJ; Zu Y; Liu GL; Song FZ
    Asian Pac J Cancer Prev; 2014; 15(2):769-73. PubMed ID: 24568493
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells.
    Song RX; Zhang Z; Chen Y; Bao Y; Santen RJ
    Endocrinology; 2007 Aug; 148(8):4091-101. PubMed ID: 17525128
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.
    Moerkens M; Zhang Y; Wester L; van de Water B; Meerman JH
    BMC Cancer; 2014 Apr; 14():283. PubMed ID: 24758408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Delayed activation of extracellular-signal-regulated kinase 1/2 is involved in genistein- and equol-induced cell proliferation and estrogen-receptor-alpha-mediated transcription in MCF-7 breast cancer cells.
    Liu H; Du J; Hu C; Qi H; Wang X; Wang S; Liu Q; Li Z
    J Nutr Biochem; 2010 May; 21(5):390-6. PubMed ID: 19427779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation.
    van Houdt WJ; Hoogwater FJ; de Bruijn MT; Emmink BL; Nijkamp MW; Raats DA; van der Groep P; van Diest P; Borel Rinkes IH; Kranenburg O
    Neoplasia; 2010 Jun; 12(6):443-52. PubMed ID: 20563247
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression.
    Andruska ND; Zheng X; Yang X; Mao C; Cherian MM; Mahapatra L; Helferich WG; Shapiro DJ
    Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4737-42. PubMed ID: 25825714
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.